Literature DB >> 27867974

Is macitentan not a treatment option for digital ulcers in systemic sclerosis?

Yoshihide Asano1.   

Abstract

Entities:  

Year:  2016        PMID： 27867974      PMCID： PMC5104633          DOI： 10.21037/atm.2016.08.67

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  25 in total

1.  Successful treatment of systemic sclerosis digital ulcers and pulmonary arterial hypertension with endothelin receptor antagonist bosentan.

Authors:  M Humbert; J Cabane
Journal:  Rheumatology (Oxford)       Date:  2003-01       Impact factor: 7.580

2.  Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis.

Authors:  J R Seibold; C P Denton; D E Furst; L Guillevin; L J Rubin; A Wells; M Matucci Cerinic; G Riemekasten; P Emery; H Chadha-Boreham; P Charef; S Roux; C M Black
Journal:  Arthritis Rheum       Date:  2010-07

3.  Bosentan blocks the antiangiogenic effects of sera from systemic sclerosis patients: an in vitro study.

Authors:  Eloisa Romano; Silvia Bellando-Randone; Mirko Manetti; Cosimo Bruni; Gemma Lepri; Marco Matucci-Cerinic; Serena Guiducci
Journal:  Clin Exp Rheumatol       Date:  2015-06-19       Impact factor: 4.473

4.  Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

Authors:  J H Korn; M Mayes; M Matucci Cerinic; M Rainisio; J Pope; E Hachulla; E Rich; P Carpentier; J Molitor; J R Seibold; V Hsu; L Guillevin; S Chatterjee; H H Peter; J Coppock; A Herrick; P A Merkel; R Simms; C P Denton; D Furst; N Nguyen; M Gaitonde; Carol Black
Journal:  Arthritis Rheum       Date:  2004-12

5.  Bosentan fosters microvascular de-remodelling in systemic sclerosis.

Authors:  S Guiducci; S Bellando Randone; C Bruni; G Carnesecchi; A Maresta; F Iannone; G Lapadula; M Matucci Cerinic
Journal:  Clin Rheumatol       Date:  2012-09-29       Impact factor: 2.980

6.  Effect of bosentan on skin fibrosis in patients with systemic sclerosis: a prospective, open-label, non-comparative trial.

Authors:  Annegret Kuhn; Merle Haust; Vincent Ruland; Ramona Weber; Pablo Verde; Gerd Felder; Christian Ohmann; Kristina Gensch; Thomas Ruzicka
Journal:  Rheumatology (Oxford)       Date:  2010-04-05       Impact factor: 7.580

7.  Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease.

Authors:  D J Abraham; R Vancheeswaran; M R Dashwood; V S Rajkumar; P Pantelides; S W Xu; R M du Bois; C M Black
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

8.  Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients.

Authors:  Lisa M Rice; Cristina M Padilla; Sarah R McLaughlin; Allison Mathes; Jessica Ziemek; Salma Goummih; Sashidhar Nakerakanti; Michael York; Giuseppina Farina; Michael L Whitfield; Robert F Spiera; Romy B Christmann; Jessica K Gordon; Janice Weinberg; Robert W Simms; Robert Lafyatis
Journal:  J Clin Invest       Date:  2015-06-22       Impact factor: 14.808

9.  Significance of plasma endothelin-1 levels in patients with systemic sclerosis.

Authors:  K Yamane; T Miyauchi; N Suzuki; T Yuhara; T Akama; H Suzuki; H Kashiwagi
Journal:  J Rheumatol       Date:  1992-10       Impact factor: 4.666

10.  Effect of treatment with iloprost with or without bosentan on nailfold videocapillaroscopic alterations in patients with systemic sclerosis.

Authors:  Valentina Cestelli; Andreina Manfredi; Marco Sebastiani; Emanuela Praino; Francesca Cannarile; Dilia Giuggioli; Clodoveo Ferri
Journal:  Mod Rheumatol       Date:  2016-06-16       Impact factor: 3.023
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.